Utah Studies Show Cannabis Extract Provides Relief to Kids with Severe Epilepsy
Early results indicate trial participants saw a 40 percent decrease in frequency and severity of seizures.
Pharmaceutical-grade cannabis already is providing some with severe epilepsy relief less than two years after clinical trials began in Utah.
The University of Utah's Division of Pediatric Neurology and Primary Children's Medical Center began in September 2014 the first of three separate clinical trials involving Epidiolex, a liquid, purified form of cannabidiol (CBD), which is a nonpsychoactive chemical in marijuana.
Early results indicate trial participants have seen about a 40 percent decrease in the frequency and severity of seizures, said neurologist Francis Filloux, an author on the study.
That number jibes with data published by GW Pharmaceuticals, the British company manufacturing the drug that approved Primary Children's as a study site. Stephen Schultz, a spokesman for the company, said officials will request a meeting with the Food and Drug Administration to discuss next steps....
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin